A

Aveo Pharmaceuticals Inc
F:VPA1

Watchlist Manager
Aveo Pharmaceuticals Inc
F:VPA1
Watchlist
Price: 13.77 EUR -0.4%
Market Cap: 478.7m EUR

Relative Value

There is not enough data to reliably calculate the relative value of VPA1.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VPA1 Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
5.5
Median 5Y
5.5
Industry
7
Forward
4.2
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-17.4
Industry
22.7
Forward
-93.9
vs History
vs Industry
Median 3Y
-22.7
Median 5Y
-21.9
Industry
19.4
vs History
vs Industry
Median 3Y
-23.8
Median 5Y
-22.9
Industry
22.6
vs History
vs Industry
Median 3Y
17.8
Median 5Y
17.2
Industry
2.6
vs History
vs Industry
Median 3Y
4.9
Median 5Y
4.9
Industry
7.3
Forward
3.9
vs History
vs Industry
Median 3Y
5.6
Median 5Y
5.6
Industry
9.4
vs History
vs Industry
Median 3Y
-19
Median 5Y
-18.6
Industry
4.6
vs History
vs Industry
Median 3Y
-19
Median 5Y
-18.5
Industry
4.5
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-19.7
Industry
5
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-19.7
Industry
3.7
vs History
vs Industry
Median 3Y
24.7
Median 5Y
24.7
Industry
4.9

Multiples Across Competitors

VPA1 Competitors Multiples
Aveo Pharmaceuticals Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Aveo Pharmaceuticals Inc
F:VPA1
476.7m EUR 5.9 -19 -20.6 -20.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 210 659 -162 598.2 -197 446.1 -195 193
US
Abbvie Inc
NYSE:ABBV
325.7B USD 5.7 78.4 15 22.1
US
Amgen Inc
NASDAQ:AMGN
147.6B USD 4.3 25 13.6 22.4
US
Gilead Sciences Inc
NASDAQ:GILD
133.5B USD 4.6 22.4 9.8 13.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.2B USD 10.3 -115.5 24.5 25.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 059.3 -525.5 -572.2 -556.9
AU
CSL Ltd
ASX:CSL
116.8B AUD 5 27.6 17 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.5B USD 4 12.6 11.1 12.5
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.8 -65.6 -59.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.3B USD 17.6 -153.3 -687.4 -344.5
P/E Multiple
Earnings Growth PEG
US
A
Aveo Pharmaceuticals Inc
F:VPA1
Average P/E: 33.2
Negative Multiple: -19
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 598.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.4
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.4
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.5 N/A N/A
AU
CSL Ltd
ASX:CSL
27.6
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -153.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Aveo Pharmaceuticals Inc
F:VPA1
Average EV/EBITDA: 15.2
Negative Multiple: -20.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.6
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.2 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -687.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Aveo Pharmaceuticals Inc
F:VPA1
Average EV/EBIT: 19.6
Negative Multiple: -20.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 193 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.1
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.4
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -344.5 N/A N/A